Friday, July 10, 2026
🇺🇸 FDA

pharma · Obesity · Type 2 diabetes

NovoThirteen

NovoThirteen drug portfolio — 67 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Bagsværd, JP HQ
PMDA registrant Type
Company details
Status
Public
HQ
Bagsværd, JP
Programs
94
Drugs
67
Patents
0
All projects Drug pipeline News & analysis
Intelligence · Drug Pipeline

NovoThirteen pipeline

Portfolio lens on 67 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

NovoThirteen drug portfolio — 67 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

67 compounds

  1. alcohol

    US regulatory status: approved.

  2. alzheimer

    Development asset linked to NovoThirteen in public FDA and regional records.

  3. antibody

    Development asset linked to NovoThirteen in public FDA and regional records.

  4. cart

    Development asset linked to NovoThirteen in public FDA and regional records.

  5. cetirizine

    Development asset linked to NovoThirteen in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.

    Mechanism
    Histamine H1 receptor antagonist

  6. chloride

    Development asset linked to NovoThirteen in public FDA and regional records.

  7. clobazam

    US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.

    Target
    GABA-A receptor; anion channel
    Mechanism
    GABA-A receptor; anion channel positive allosteric modulator

  8. combination

    Development asset linked to NovoThirteen in public FDA and regional records.

  9. concizumab

    Blood and blood forming organs (B02)

    US regulatory status: approved. Molecular target: Tissue factor pathway inhibitor.

    Target
    Tissue factor pathway inhibitor
    Mechanism
    Tissue factor pathway inhibitor inhibitor

  11. control

    Development asset linked to NovoThirteen in public FDA and regional records.

  12. dapagliflozin

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.

    Target
    Sodium/glucose cotransporter 2
    Mechanism
    Sodium/glucose cotransporter 2 inhibitor

  13. decitabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.

    Target
    DNA (cytosine-5)-methyltransferase 1
    Mechanism
    DNA (cytosine-5)-methyltransferase 1 inhibitor

  14. dose

    Development asset linked to NovoThirteen in public FDA and regional records.

  15. doxylamine succinate

    US regulatory status: approved. Molecular target: Histamine H1 receptor.

    Target
    Histamine H1 receptor
    Mechanism
    Histamine H1 receptor antagonist

  16. enalapril

    Development asset linked to NovoThirteen in public FDA and regional records. Mechanism: Angiotensin-converting enzyme inhibitor.

    Mechanism
    Angiotensin-converting enzyme inhibitor

  17. erythromycin

    US regulatory status: approved. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Bacterial 70S ribosome inhibitor

  18. estradiol

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist

  19. finerenone

    Cardiovascular system (C09)

    US regulatory status: approved. Molecular target: Mineralocorticoid receptor.

    Target
    Mineralocorticoid receptor
    Mechanism
    Mineralocorticoid receptor antagonist

  20. glargine

    Development asset linked to NovoThirteen in public FDA and regional records. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  21. glucagon hydrochloride

    US regulatory status: approved. Molecular target: Glucagon receptor.

    Target
    Glucagon receptor
    Mechanism
    Glucagon receptor agonist

  22. hexachlorophene

    US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.

    Target
    Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
    Mechanism
    Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor

  24. hydroxycarbamide

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in NovoThirteen's portfolio. Molecular target: Ribonucleoside-diphosphate reductase RR1.

    Target
    Ribonucleoside-diphosphate reductase RR1
    Mechanism
    Ribonucleoside-diphosphate reductase RR1 inhibitor

  25. hydroxyurea

    US regulatory status: approved. Molecular target: Ribonucleoside-diphosphate reductase RR1.

    Target
    Ribonucleoside-diphosphate reductase RR1
    Mechanism
    Ribonucleoside-diphosphate reductase RR1 inhibitor

  26. individual

    Development asset linked to NovoThirteen in public FDA and regional records.

  27. inhibitor

    Development asset linked to NovoThirteen in public FDA and regional records.

  28. inhibitors

    Development asset linked to NovoThirteen in public FDA and regional records.

  29. injection

    Development asset linked to NovoThirteen in public FDA and regional records.

  30. insulin

    Development asset linked to NovoThirteen in public FDA and regional records. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  31. insulin aspart

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  33. insulin degludec

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  36. insulin detemir

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  37. insulin glargine

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  38. insulin glargine recombinant

    US regulatory status: approved. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  39. insulin human

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  40. insulin icodec

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  41. insulin isophane human

    Development asset linked to NovoThirteen in public FDA and regional records. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  42. insulin neutral human

    Development asset linked to NovoThirteen in public FDA and regional records. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  43. interleukin-

    Development asset linked to NovoThirteen in public FDA and regional records.

  44. liraglutide

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.

    Target
    Glucagon-like peptide 1 receptor
    Mechanism
    Glucagon-like peptide 1 receptor agonist

  45. management

    Development asset linked to NovoThirteen in public FDA and regional records.

  46. medroxyprogesterone acetate

    US regulatory status: approved. Molecular target: Progesterone receptor.

    Target
    Progesterone receptor
    Mechanism
    Progesterone receptor agonist

  47. metformin

    Development asset linked to NovoThirteen in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.

    Mechanism
    Mitochondrial complex I (NADH dehydrogenase) inhibitor

  48. monoclonal

    Development asset linked to NovoThirteen in public FDA and regional records.

  49. normal

    Development asset linked to NovoThirteen in public FDA and regional records.

  50. ophthalmic

    Development asset linked to NovoThirteen in public FDA and regional records.

  51. paracetamol

    Development asset linked to NovoThirteen in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.

    Target
    Fatty-acid amide hydrolase 1
    Mechanism
    Anandamide amidohydrolase inhibitor

  52. phentermine hydrochloride

    US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.

    Target
    Sodium-dependent noradrenaline transporter
    Mechanism
    Norepinephrine transporter releasing agent

  53. placebo

    Development asset linked to NovoThirteen in public FDA and regional records.

  54. polidocanol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  55. progression

    Development asset linked to NovoThirteen in public FDA and regional records.

  56. semaglutide

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.

    Target
    Glucagon-like peptide 1 receptor
    Mechanism
    Glucagon-like peptide 1 receptor agonist

  58. solution

    Development asset linked to NovoThirteen in public FDA and regional records.

  59. somapacitan

    Systemic hormonal preparations (H01)

    Systemic hormonal preparations (H01) compound in NovoThirteen's portfolio. Molecular target: Growth hormone receptor.

    Target
    Growth hormone receptor
    Mechanism
    Growth hormone receptor agonist

  60. somatropin

    Systemic hormonal preparations (H01)

    US regulatory status: approved. Molecular target: Growth hormone receptor.

    Target
    Growth hormone receptor
    Mechanism
    Growth hormone receptor agonist

  61. standard

    Development asset linked to NovoThirteen in public FDA and regional records.

  62. subcutaneous

    Development asset linked to NovoThirteen in public FDA and regional records.

  63. tablet

    Development asset linked to NovoThirteen in public FDA and regional records.

  64. tablets

    Development asset linked to NovoThirteen in public FDA and regional records.

  65. tirzepatide

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Gastric inhibitory polypeptide receptor.

    Target
    Gastric inhibitory polypeptide receptor
    Mechanism
    Glucagon-like peptide 1 receptor agonist

  66. treatment

    Development asset linked to NovoThirteen in public FDA and regional records.

  67. tretinoin

    US regulatory status: approved. Molecular target: Retinoic acid receptor.

    Target
    Retinoic acid receptor
    Mechanism
    Retinoic acid receptor agonist

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.